11:30 am–12:30 pm Friday, September 6

Livers, Kidneys, and Germ Cells – Oh My! Helping Nurses Understand the Children’s Oncology Group Approach to Unique Childhood Cancers (C217)

coglogoLiver, kidney (renal cell carcinoma), and germ cell tumors are rare cancer diagnoses in children and adolescents (Ward E., et al 2014). Enrollment on clinical trials is essential for the continued improvements in outcomes for children with cancer; however, uncommon childhood malignancies make the conduct of these trials a significant challenge (Czauderna P., et al 2016).

Read more...
5:00–6:00 pm Thursday, September 5

Infant ALL: Rearranged for the Big Screen! Providing Care on COG AALL15P1, Nurses in a Leading Role! (C211)

coglogoAcute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with 5-year overall survival rates exceeding 90% (Hunger, Lu, Devidas, Camitta, Gaynon, Winick, 2012). Unfortunately, infants with ALL are an exception to the improving survival trends and remain one of the most challenging populations in pediatric hematology/oncology (Kotecha, Gottardo, Kees, Cole, 2014).

Read more...
3:45–4:45 pm Thursday, September 5

Navigating 131I-MIBG and CAR T 19, in COG trials ANBL1531 and AALL1721: Sharing Care and Strategies for Success (C205)

coglogoThe Children’s Oncology Group (COG) is committed to improving outcomes for pediatric oncology patients with the high-risk disease through clinical trials. Despite tremendous advancements in pediatric oncology treatment, survival in two patient populations remains inferior. Patients with high-risk neuroblastoma have a projected 3-year event-free survival of 73% (Park et al., 2016), and patients with precursor B lineage acute lymphoblastic leukemia with positive minimal residual disease at the end of consolidation have a projected 5-year disease-free survival of 39% (Borowitz et al., 2015).

Read more...
2:15–3:15 pm Saturday, September 7

HCT & Gene Therapy in the Treatment of Inherited Metabolic Disorders (231)

Inherited metabolic disorders (IMDs) are a diverse group of diseases caused by genetic mutations that result in potentially lethal enzymatic abnormalities. Some IMDs such as adrenoleukodystrophy and mucopolysaccharidosis can be diagnosed by routine newborn screen, while others will present later in life when symptoms appear.

Read more...
Speaker:
Victoria Szenes, MS RN CPNP
CNE Hours
1
11:30 am–12:30 pm Saturday, September 7

Creating the Spark - Inspire Learning with Interactive Activities for the Chemotherapy/Biotherapy Provider Course (226)

The 4th edition of the APHON Chemotherapy and Biotherapy Curriculum was published earlier this year. Extensive updates to the 4th edition book and live instructor course created a need to provide ongoing support for the 550 instructors as they familiarize themselves with the updated content and revised lectures. Central to the updated material is a focus on interactive teaching strategies.

Read more...
11:30 am–12:30 pm Saturday, September 7

The Autoimmune Cytopenias: Deactivating the Self-Destruct Sequence (225)

Autoimmune cytopenias include autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), autoimmune neutropenia (AIN), and Evan’s syndrome (ES). This diverse group of hematologic disorders is characterized by the production of autoantibodies by the patient’s own immune system against hematopoietic cells in the blood or bone marrow.

Read more...
Speaker:
Karyn Brundige, MSN CPNP
CNE Hours
1
4:15–5:15 pm Friday, September 6

Advances in Pediatric Neuro-Oncology in the Molecular Era (218)

Pediatric CNS tumors as a group represent the most common solid tumor in childhood and encompass a wide variety of diagnoses, from benign to malignant. Recent advances in molecular profiling have led to significant changes in the classification of pediatric CNS tumors, with a positive impact on diagnosis, prognosis, and treatment. Gliomas have undergone reclassification with emphasis on molecular profile over histology, leading to a redefinition of traditional low-grade versus high-grade glioma.

Read more...
Speaker:
Cheryl Fischer, MSN RN CPNP
CNE Hours
1
5:00–6:00 pm Thursday, September 5

Decoding the Mystery of Gene Therapy – An Overview for Nursing (208)

The decoding of the human genome has provided scientists and researchers a new pathway to developing potential curative therapies for life-threatening or otherwise fatal illnesses. The development of these gene therapies is moving at lightning speed, translating this novel therapy from the bench to the bedside at a record pace. What was once thought of as a highly experimental approach, these therapies are quickly becoming standard of care, as demonstrated by the recent Food and Drug Administration (FDA) approval of several gene therapies, specifically Chimeric Antigen Receptor (CAR) T cell for B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma. These therapies are complex both in their scientific development and, more importantly, in their clinical delivery.

Read more...
Speaker:
Colleen Dansereau, MSN RN CPN
CNE Hours
1

I-131 Metaiodobenzylguanidine Therapy: It Takes a Village; The Experience Gained at Three Institutions (007)

Despite aggressive treatment, patients with high-risk neuroblastoma have a 40%-60% chance of suffering a relapse. Recent improvements in survival have resulted from changes in treatment during consolidation (tandem myeloablative stem cell transplants) and post-consolidation (immunotherapy) time periods. The neuroblastoma community has been struggling to identify treatments that can be integrated into induction therapy with the goal of further improving survival rates. Consequently, I-131 Metaiodobenzylguanidine (I-131 MIBG) has been moved to the induction treatment period due to its history of success in the treatment of patients with relapsed refractory disease (approximately 40% of patients have a favorable response to treatment with I-131 MIBG).

Read more...
Speaker:

Jennifer Saggio, MSN CRNP
Dawn Bartock, MSN CPNP CPHON®
Sage Heyman, LSW
Dennis Reid, BSN CPHON®
Alyssa Yost, BSN RN

ssa Yost, BSN RN
Fee
$110 for APHON members
$140 for non-members
CNE Hours
3.25
Subscribe to this RSS feed